SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Clinical: ARO-MAPT-SC Tau ASO Trial (NCT07221344)

clinical 1,486 words KG: ent-clin-4b0c8c48 2026-03-28

kind:clinical-trial section:clinical-trials state:published

Contents

ARO-MAPT-SC Tau ASO Trial (NCT07221344)

Knowledge Graph

Related Hypotheses (24)

Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55 Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51 Dual-Circuit Tau Vulnerability Cascade
Score: 0.50 Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49 Cholinergic Basal Forebrain-Hippocampal Circuit Protection
Score: 0.49

Microglial-Mediated Tau Clearance Dysfunction via TREM2 Rece
Score: 0.49 Locus Coeruleus-Hippocampal Circuit Protection
Score: 0.48 Microglial Exosome-Mediated Tau Propagation
Score: 0.47 Dual-Circuit Tau Vulnerability Cascade with Glial-Mediated A
Score: 0.46 Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in
Score: 0.46 Microglial TREM2-Mediated Tau Phagocytosis Impairment
Score: 0.44 Glymphatic-Cholinergic Tau Clearance Cascade
Score: 0.43 Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59 Competitive APOE4 Domain Stabilization Peptides
Score: 0.56 APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54 Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53 Lysosomal Calcium Channel Modulation Therapy
Score: 0.49 Lysosomal Enzyme Trafficking Correction
Score: 0.49 APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49 APOE Isoform Expression Across Glial Subtypes
Score: 0.48 Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46 Lysosomal Membrane Repair Enhancement
Score: 0.45 APOE Isoform Conversion Therapy
Score: 0.44 Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.43

Related Analyses (30)

Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived 4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived

Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Mitochondrial transfer between neurons and glia
neurodegeneration · archived Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived Synaptic pruning by microglia in early AD
neurodegeneration · archived Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived Circuit-level neural dynamics in neurodegeneration
neuroscience · archived Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived

Related Experiments (7)

Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
validation · proposed · Score: 0.40 Cytochrome Therapeutics
clinical · proposed · Score: 0.40 Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Tau ASO Therapy
validation · proposed · Score: 0.40

Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90 Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80

SciDEX — scidex.ai — Dashboard | Atlas